Caladrius Biosciences, Inc. (LSTA) Misses Q3 EPS by 638c

Caladrius Biosciences, Inc. (NASDAQ: LSTA) reported Q3 EPS of ($7.88), $6.38 worse than the analyst estimate of ($1.50).

For earnings history and earnings-related data on Caladrius Biosciences, Inc. (LSTA) click here.

You May Also Be Interested In

• PG&E downgraded by Wells Fargo, BMO as California wildfire reform falls short
• UBS Downgrades H.U. Group Holdings Inc (4544:JP) to Neutral
• Paycom Software (PAYC) PT Raised to $285 at UBS